Drug
Vutrisiran
Vutrisiran: highest development phase Phase 3, developed by Alnylam Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Vutrisiran NCT06679946 | Phase 3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy |
| Vutrisiran NCT04153149 | Phase 3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy |
Latest
No recent events.
Follow Vutrisiran on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.